Povidone-Iodine: Uses, Side Effects, Dosage - Drugvu

ℹ️ Compiled from public regulatory records · Last regulator revision: May 15, 2026🚩 Report this page

Povidone-Iodine

Active ingredient · 6 therapeutic classes

Sold as sterile · Betadine · Aplicare · PVP Iodine · MediChoice PVP

US FDAGB MHRA

Drug class: Other Antiinfectives and Antiseptics
Availability: Over-the-counter
Routes: Topical, Cutaneous, Nasal
Markets covered: 2
Products on record: 43
FDA reports (12 mo): 254

G01AXOther Antiinfectives and Antiseptics D08AGIodine Products D09AAMedicated Dressings With Antiinfectives D11ACMedicated Shampoos R02AAAntiseptics S01AXOther Antiinfectives

Overview

Povidone-Iodine is an active pharmaceutical ingredient in the Other Antiinfectives and Antiseptics group (G01AX). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.

Regulatory status by market

Market	Regulator	Products	Last revision
US United States	FDA	33	February 25, 2026
GB United Kingdom	MHRA	10	May 15, 2026

USUnited States· FDA

33 products

Uses

USOfficial regulatory label· revised January 2, 2025[1]

Uses First aid to help prevent infection in minor cuts scrapes burns

How to take

USOfficial regulatory label

GBUnited Kingdom· MHRA

10 products

Uses

GBOfficial regulatory label· revised November 1, 2024[2]

Betadine Throat Spray is indicated for oral hygiene and acute treatment of oromucosal and pharyngeal infections of viral, bacterial or fungal origin such as: Sore throat (pharyngitis).

How to take

Sources & citations

[1]FDA DailyMed · 00002127-02bc-4c… · revised January 2, 2025 [PDF]
[2]MHRA (UK) · PL584420002 · revised November 1, 2024
[3]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.

Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.

Side effects & warnings

GBOfficial regulatory label· Adverse reactions· revised November 1, 2024[2]

The following frequencies are the basis for assessing undesirable effects: • Very common (≥ 1/10) • Common (≥ 1/100 to < 1/10) • Uncommon (≥ 1/1,000 to <1/100) • Rare (≥ 1/10,000 to < 1/1,000) • Very rare (<1/10,000) • Not known (cannot be estimated from the available data) Immune system disorders Rare Hypersensitivity Very rare Anaphylactic reaction Endocrine disorders Very rare Hyperthyroidism (sometimes with symptoms such as tachycardia or restlessness) * Unknown Hypothyroidism *** Metabolism and nutrition disorders Unknown Electrolyte imbalance **, Metabolic acidosis ** Skin and subcutaneous disorders Very rare Angioedema Respiratory, thoracic and mediastinal disorders Unknown Pneumonitis Renal and urinary disorders Unknown Acute renal failure**, Blood osmolarity abnormal** * In patients with a history of thyroid disease (see under Special Warnings and Special Precautions for Use) following a notable uptake of iodine ** May occur following uptake of large amounts of povidone iodine *** Hypothyroidism following prolonged or extensive use of povidone iodine Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important.
It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

GBOfficial regulatory label· Warnings and precautions· revised November 1, 2024[2]

In instances of local irritation or sensitivity, discontinue use. In oropharyngeal use, precautions should be taken to prevent aspiration of Betadine Throat Spray into the respiratory tract as this may cause complications such as pneumonitis.
This may particularly occur in intubated patients. This medicine contains 40 mg of alcohol (ethanol) in each dose (spray). The amount in each dose (spray) of this medicine is equivalent to less than 1 ml of beer or wine. The small amount of alcohol in this medicine should not have any noticeable effects.
Special caution is needed in pregnant and breast-feeding patients. 6). For use in the mouth and throat only.

This is not medical advice. Consult a qualified healthcare professional.

Overview

Regulatory status by market

USUnited States· FDA

GBUnited Kingdom· MHRA

Drugs in the same class

Sources & citations